Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE) traded up 2.2% on Monday . The company traded as high as $67.93 and last traded at $67.46, with a volume of 386,468 shares traded. The stock had previously closed at $66.00.

A number of equities research analysts have recently weighed in on the company. Morgan Stanley reiterated a “hold” rating on shares of Ultragenyx Pharmaceutical in a research report on Wednesday, June 8th. JMP Securities reiterated a “buy” rating and issued a $84.00 price objective (up from $80.00) on shares of Ultragenyx Pharmaceutical in a research report on Wednesday, June 8th. Jefferies Group reiterated a “buy” rating and issued a $109.00 price objective on shares of Ultragenyx Pharmaceutical in a research report on Wednesday, June 8th. Zacks Investment Research lowered Ultragenyx Pharmaceutical from a “hold” rating to a “sell” rating in a research report on Thursday, April 28th. Finally, Credit Suisse Group AG reiterated a “buy” rating and issued a $101.00 price objective on shares of Ultragenyx Pharmaceutical in a research report on Wednesday, May 25th. Three analysts have rated the stock with a hold rating, fifteen have issued a buy rating and one has issued a strong buy rating to the company’s stock. The company currently has a consensus rating of “Buy” and a consensus target price of $99.10.

The firm has a 50-day moving average of $59.64 and a 200-day moving average of $61.80. The firm’s market capitalization is $2.72 billion.

Ultragenyx Pharmaceutical (NASDAQ:RARE) last issued its quarterly earnings results on Monday, August 8th. The biopharmaceutical company reported ($1.46) earnings per share for the quarter, missing the consensus estimate of ($1.44) by $0.02. During the same period in the previous year, the firm posted ($0.83) earnings per share. On average, equities analysts expect that Ultragenyx Pharmaceutical Inc. will post ($5.93) EPS for the current fiscal year.

In other news, insider Sunil Agarwal sold 649 shares of the stock in a transaction that occurred on Thursday, July 21st. The stock was sold at an average price of $52.68, for a total value of $34,189.32. The sale was disclosed in a filing with the SEC, which is available through this hyperlink. Also, CEO Emil D. Kakkis sold 20,000 shares of the stock in a transaction that occurred on Friday, July 15th. The stock was sold at an average price of $50.85, for a total value of $1,017,000.00. Following the completion of the sale, the chief executive officer now owns 513,597 shares in the company, valued at $26,116,407.45. The disclosure for this sale can be found here.

Other large investors have modified their holdings of the company. Dimensional Fund Advisors LP increased its stake in shares of Ultragenyx Pharmaceutical by 9.9% in the fourth quarter. Dimensional Fund Advisors LP now owns 57,172 shares of the biopharmaceutical company’s stock valued at $6,414,000 after buying an additional 5,139 shares during the last quarter. Trexquant Investment LP acquired a new stake in shares of Ultragenyx Pharmaceutical during the fourth quarter valued at $1,010,000. Finally, Schwab Charles Investment Management Inc. increased its stake in shares of Ultragenyx Pharmaceutical by 8.1% in the fourth quarter. Schwab Charles Investment Management Inc. now owns 153,788 shares of the biopharmaceutical company’s stock valued at $17,252,000 after buying an additional 11,497 shares during the last quarter.

Ultragenyx Pharmaceutical Inc is a clinical-stage biopharmaceutical company. The Company is focused on the identification, acquisition, development, and commercialization of products for the treatment of genetic diseases. The Company is engaged in the identification, acquisition, development and commercialization of products for the treatment of rare and ultra-rare diseases segment.

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.